A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 22; no. 1; pp. 47 - 54
• Main Authors: Hardy, Jennifer, Niman, Stephanie, Goldfaden, Rebecca F., Ashchi, Majdi, Bisharat, Mohannad, Huston, Jessica, Hartmann, Heather, Choksi, Rushab
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 2022; Springer Nature B.V
• Subjects: Apolipoproteins; Atherosclerosis; Cardiology; Cardiovascular disease; Health risk assessment; Humans; Hypolipidemic Agents - pharmacology; Lipids; Lipoprotein(a) - drug effects; Lipoproteins; Medical research; Medicine; Medicine & Public Health; Pharmacology/Toxicology; Pharmacotherapy; Population; Proteins; Review Article; Thromboembolism
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/s40256-021-00499-1

Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, some populations with elevated Lp(a) biomarkers remain at an increased risk for cardiovascular (CV) disease. Residual CV risk has led researchers to inquire about how lowering Lp(a) can be used as a potential preventative therapy in reducing CV events. This review aims to present and discuss the current clinical and scientific evidence pertaining to pelacarsen.